Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
JAMA (2021) Vol. 326, Iss. 19, pp. 1930-1930
Open Access | Times Cited: 161

Showing 1-25 of 161 citing articles:

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 13, pp. 1207-1220
Open Access | Times Cited: 623
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 416
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 23, pp. 2201-2212
Open Access | Times Cited: 377
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 831-837
Open Access | Times Cited: 372
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 19, pp. 1804-1816
Open Access | Times Cited: 362
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
Peter Nordström, Marcel Ballin, Anna Nordström
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 6, pp. 781-790
Open Access | Times Cited: 258
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
Environmental Research (2022) Vol. 209, pp. 112911-112911
Open Access | Times Cited: 233
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112443-112443
Open Access | Times Cited: 145
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
Thiago Cerqueira‐Silva, Jason R. Andrews, Viviane Boaventura, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 6, pp. 791-801
Open Access | Times Cited: 120
Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
Ariel Hammerman, Ruslan Sergienko, Michael Friger, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 13, pp. 1221-1229
Open Access | Times Cited: 115
Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Roberto Bertollini
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1091-1093
Open Access | Times Cited: 105
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Hiam Chemaitelly, Nico Nagelkerke, Houssein H. Ayoub, et al.
Journal of Travel Medicine (2022) Vol. 29, Iss. 8
Open Access | Times Cited: 90
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 82
Risk of reinfection and disease after SARS‐CoV‐2 primary infection: Meta‐analysis
Maria Elena Flacco, Cecilia Acuti Martellucci, Valentina Baccolini, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 10
Open Access | Times Cited: 74
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Jan Van Elslande, Matthijs Oyaert, Natalie Lorent, et al.
Diagnostic Microbiology and Infectious Disease (2022) Vol. 103, Iss. 1, pp. 115659-115659
Open Access | Times Cited: 73
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study
Annabel Powell, Freja Kirsebom, Julia Stowe, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 4, pp. 435-444
Open Access | Times Cited: 73
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 14, pp. 1329-1331
Open Access | Times Cited: 72
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study
Chenyuan Qin, Ruitong Wang, Liyuan Tao, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 89-89
Open Access | Times Cited: 68
Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Roberto Bertollini
New England Journal of Medicine (2022) Vol. 386, Iss. 8, pp. 799-800
Open Access | Times Cited: 67
mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine
Jana Sophia Buhre, Tamás Pongrácz, Inga Künsting, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 63
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, et al.
Nature (2025)
Open Access | Times Cited: 2
Disease severity during SARS-COV-2 reinfection: a nationwide study
Anna Mensah, Joanne Lacy, Julia Stowe, et al.
Journal of Infection (2022) Vol. 84, Iss. 4, pp. 542-550
Open Access | Times Cited: 64
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Michel Obéid, Madeleine Suffiotti, Céline Pellaton, et al.
JAMA Oncology (2022) Vol. 8, Iss. 5, pp. e220446-e220446
Open Access | Times Cited: 62
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 12, pp. e944-e955
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top